Decoding Sarcoma Drug Resistance: From Molecular Mechanisms to Precision Interventions.

INTRODUCTION

This study aims to systematically synthesize current knowledge on the molecular and microenvironmental mechanisms driving sarcoma drug resistance, and to evaluate emerging precision strategies for overcoming these obstacles.

METHODS

We conducted a comprehensive literature review (PubMed, Web of Science, Embase; inception- 31 July 2025) using MeSH and free-text terms relating to sarcoma, drug resistance, biomarkers, and precision medicine. Inclusion criteria were peer-reviewed original or review studies in human or pre-clinical sarcoma models reporting resistance mechanisms or counter-strategies. Data were qualitatively categorized by resistance pathways (efflux pumps, DNA repair, apoptosis inhibition, secondary mutations, and immune evasion) and linked to therapeutic countermeasures.

RESULTS

ABC transporter over-expression (especially P-gp) and heightened DNA repair via homologous recombination were recurrent chemo-resistance drivers. Targeted-therapy failure was dominated by secondary KIT/PDGFRA or NTRK mutations, bypass signaling (PI3K/AKT ↔ RAS/MAPK), and epithelial- mesenchymal transition. Immune escape occurred through antigen loss, MHC-I down-regulation, adenosine- rich immunosuppressive microenvironments, and T-cell exhaustion (PD-1/CTLA-4 up-regulation). Epigenetic dysregulation (EZH2, HDAC, DNMT) further fostered stem-like survival. Liquid-biopsy ctDNA enabled real-time resistance monitoring. Next-generation TKIs, dual-pathway inhibitors, epigenetic drugs, and rationally designed chemo-immuno combinations showed synergistic activity in pre-clinical and early clinical studies.

DISCUSSION: Integrating multi-omics profiling, liquid biopsies, and patient-derived organoids into adaptive trial designs can individualize therapy sequences and delay resistance. Limitations include heterogeneous sarcoma biology, limited clinical validation, and economic barriers to the implementation of precision.

CONCLUSION

Resistance to drugs in sarcoma is multifactorial and changeable. Nevertheless, fusing mechanistic knowledge with biomarker - guided combination/sequential therapies offers a clear way to improve patient situations.